[{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Haystack Oncology","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Haystack Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Haystack Oncology \/ Lisata Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Haystack Oncology \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Cend Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Cend Therapeutics"},{"orgOrder":0,"company":"NuCana","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Fosifloxuridine Nafalbenamide","moa":"||antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NuCana \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NuCana \/ Undisclosed"},{"orgOrder":0,"company":"NuCana","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Fosifloxuridine Nafalbenamide","moa":"||antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NuCana \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NuCana \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Leucovorin","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"University of Pennsylvania","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2022","type":"Agreement","leadProduct":"5 Fluorouracil","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ University of Pennsylvania","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ University of Pennsylvania"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncolytics Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Endovion","moa":"||Chloride channel unspecific (ClC)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scandion Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Scandion Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Endovion","moa":"||Chloride channel unspecific (ClC)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scandion Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Scandion Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Folinic Acid","moa":"||Claudin-18","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Leucovorin","moa":"||Claudin-18","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Leucovorin","moa":"||Claudin-18","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leucovorin","moa":"||Claudin-18","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Amplia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amplia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Amplia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amplia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"Dutch Pancreatic Cancer Group | Dutch Cancer Society","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Dihydrofolate reductase (DHFR)","graph1":"Oncology","graph2":"Phase III","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Dutch Pancreatic Cancer Group | Dutch Cancer Society","highestDevelopmentStatusID":"10","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Dutch Pancreatic Cancer Group | Dutch Cancer Society"},{"orgOrder":0,"company":"Xenetic Biosciences","sponsor":"PeriNess","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"5-fluorouracil","moa":"||DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Xenetic Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenetic Biosciences \/ PeriNess","highestDevelopmentStatusID":"6","companyTruncated":"Xenetic Biosciences \/ PeriNess"},{"orgOrder":0,"company":"MedStar Washington Hospital Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"MedStar Washington Hospital Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MedStar Washington Hospital Center \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MedStar Washington Hospital Center \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merrimack Pharmaceuticals","amount2":1.03,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"Infusion","sponsorNew":"Merrimack Pharmaceuticals \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Merrimack Pharmaceuticals \/ Ipsen"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Cetuximab Beta","moa":"||EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"INCB001158","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calithera Biosciences \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Calithera Biosciences \/ Incyte Corporation"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Panitumumab","moa":"||Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"Bemarituzumab","moa":"||Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Five Prime Therapeutics","amount2":1.8999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.8999999999999999,"dosageForm":"Infusion","sponsorNew":"Five Prime Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Five Prime Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"Bemarituzumab","moa":"||Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Five Prime Therapeutics","amount2":1.8999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.8999999999999999,"dosageForm":"Infusion","sponsorNew":"Five Prime Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Five Prime Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Five Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Five Prime Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Five Prime Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BOLD-100","moa":"||GRP78 upregulation pathway","graph1":"Oncology","graph2":"Phase II","graph3":"Bold Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bold Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bold Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"XBiotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||IL1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"XBiotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/ Undisclosed"},{"orgOrder":0,"company":"XBiotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||IL1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"XBiotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Celyad","sponsor":"Fortress Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2021","type":"Private Placement","leadProduct":"5 Fluorouracil","moa":"||NKG2 D activating NK receptor (KLRK1)","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Fortress Investment Group","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Fortress Investment Group"},{"orgOrder":0,"company":"Celyad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2 D activating NK receptor (KLRK1)","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Undisclosed"},{"orgOrder":0,"company":"Celyad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2 D activating NK receptor (KLRK1)","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Undisclosed"},{"orgOrder":0,"company":"Celyad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2 D activating NK receptor (KLRK1)","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Undisclosed"},{"orgOrder":0,"company":"Celyad","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2 D activating NK receptor (KLRK1)","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Merck & Co"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Devimistat","moa":"||PDK","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Devimistat","moa":"||PDK","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Devimistat","moa":"||PDK","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ability Pharma","sponsor":"CTI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Ibrilatazar","moa":"||Peroxisome proliferator-activated receptor (PPAR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ability Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Ability Pharma \/ CTI Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Ability Pharma \/ CTI Life Sciences"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Merck Group | Guardant Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase III","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charite University, Berlin, Germany \/ Merck Group | Guardant Health","highestDevelopmentStatusID":"10","companyTruncated":"Charite University, Berlin, Germany \/ Merck Group | Guardant Health"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"TFS Trial Form Support","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scandion Oncology \/ TFS Trial Form Support","highestDevelopmentStatusID":"7","companyTruncated":"Scandion Oncology \/ TFS Trial Form Support"},{"orgOrder":0,"company":"Roger Williams Medical Center","sponsor":"TriSalus Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase I","graph3":"Roger Williams Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roger Williams Medical Center \/ TriSalus Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Roger Williams Medical Center \/ TriSalus Life Sciences"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Ipsen"},{"orgOrder":0,"company":"GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil","sponsor":"Jules Bordet Institute | Belgian Group of Digestive Oncology | University Hospital St Luc, Brussels","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BRAZIL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase II","graph3":"GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil \/ Jules Bordet Institute | Belgian Group of Digestive Oncology | University Hospital St Luc, Brussels","highestDevelopmentStatusID":"8","companyTruncated":"GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil \/ Jules Bordet Institute | Belgian Group of Digestive Oncology | University Hospital St Luc, Brussels"},{"orgOrder":0,"company":"Ralf Hofheinz","sponsor":"German Cancer Aid | IKF Nordwest | German Rectal Cancer Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase III","graph3":"Ralf Hofheinz","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ralf Hofheinz \/ German Cancer Aid | IKF Nordwest | German Rectal Cancer Study Group","highestDevelopmentStatusID":"10","companyTruncated":"Ralf Hofheinz \/ German Cancer Aid | IKF Nordwest | German Rectal Cancer Study Group"},{"orgOrder":0,"company":"Chungnam National University Hospital","sponsor":"Boryung Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Chungnam National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chungnam National University Hospital \/ Boryung Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Chungnam National University Hospital \/ Boryung Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"National Cheng-Kung University Hospital","sponsor":"TTY BIOPHARM CO LTD | Kaohsiung Veterans General Hospital. | Taipei Veterans General Hospital | China Medical University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase II","graph3":"National Cheng-Kung University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cheng-Kung University Hospital \/ TTY BIOPHARM CO LTD | Kaohsiung Veterans General Hospital. | Taipei Veterans General Hospital | China Medical University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"National Cheng-Kung University Hospital \/ TTY BIOPHARM CO LTD | Kaohsiung Veterans General Hospital. | Taipei Veterans General Hospital | China Medical University Hospital"},{"orgOrder":0,"company":"Cancer Research Antwerp","sponsor":"Kom Op Tegen Kanker | Naslund Medical AB | Varian Medical Systems","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cancer Research Antwerp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Research Antwerp \/ Kom Op Tegen Kanker | Naslund Medical AB | Varian Medical Systems","highestDevelopmentStatusID":"1","companyTruncated":"Cancer Research Antwerp \/ Kom Op Tegen Kanker | Naslund Medical AB | Varian Medical Systems"},{"orgOrder":0,"company":"Canadian Cancer Trials Group","sponsor":"Alliance for Clinical Trials in Oncology | ECOG-ACRIN Cancer Research Group | NRG Oncology | SWOG Cancer Research Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase III","graph3":"Canadian Cancer Trials Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canadian Cancer Trials Group \/ Alliance for Clinical Trials in Oncology | ECOG-ACRIN Cancer Research Group | NRG Oncology | SWOG Cancer Research Network","highestDevelopmentStatusID":"10","companyTruncated":"Canadian Cancer Trials Group \/ Alliance for Clinical Trials in Oncology | ECOG-ACRIN Cancer Research Group | NRG Oncology | SWOG Cancer Research Network"},{"orgOrder":0,"company":"ECOG-ACRIN Cancer Research Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ECOG-ACRIN Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute","highestDevelopmentStatusID":"9","companyTruncated":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute"},{"orgOrder":0,"company":"Kimberly Perez","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase II","graph3":"Kimberly Perez","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kimberly Perez \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Kimberly Perez \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||Serine\/threonine-protein kinase PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cardiff Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||Serine\/threonine-protein kinase PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cardiff Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||Serine\/threonine-protein kinase PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cardiff Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||Serine\/threonine-protein kinase PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cardiff Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||Serine\/threonine-protein kinase PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cardiff Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||Serine\/threonine-protein kinase PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardiff Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Inspirna","sponsor":"Sands Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series D Financing","leadProduct":"Irinotecan","moa":"||SLC6A8\/CKB pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Inspirna \/ Sands Capital","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Sands Capital"},{"orgOrder":0,"company":"Inspirna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||SLC6A8\/CKB pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inspirna \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Undisclosed"},{"orgOrder":0,"company":"Inspirna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||SLC6A8\/CKB pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inspirna \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Undisclosed"},{"orgOrder":0,"company":"Inspirna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan HCl Trihydrate","moa":"||SLC6A8\/CKB pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inspirna \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"||Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"FivepHusion","sponsor":"Syneos Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2023","type":"Collaboration","leadProduct":"Fluorouracil","moa":"||Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FivepHusion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FivepHusion \/ Syneos Health","highestDevelopmentStatusID":"7","companyTruncated":"FivepHusion \/ Syneos Health"},{"orgOrder":0,"company":"FivepHusion","sponsor":"Allarity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2023","type":"Collaboration","leadProduct":"Fluorouracil","moa":"||Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FivepHusion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FivepHusion \/ Allarity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"FivepHusion \/ Allarity Therapeutics"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||Toll-like receptor 3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Undisclosed"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncotelic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oncotelic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncotelic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oncotelic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mabxience","sponsor":"Zentiva","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Bevacizumab","moa":"||Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabxience \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Mabxience \/ Zentiva"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||Wnt\/beta-catenin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sapience Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||Wnt\/beta-catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sapience Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Calcium Folinate
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
